Skip to main content

Table 1 List of 33 plasma metabolomes in HER2-positive breast cancer patients that were significantly altered (FDR < 0.05) at 2 weeks after completion of doxorubicin treatment

From: Changes in blood metabolomes as potential markers for severity and prognosis in doxorubicin-induced cardiotoxicity: a study in HER2-positive and HER2-negative breast cancer patients

Significantly altered metabolomes (Total 33 metabolomes)

Fold change when compared to baseline

• Amino acids

 Glycine

0.82 ± 0.07

 Isoleucine and Leucine

1.19 ± 0.05

 Phenylalanine

1.12 ± 0.04

• Branched-chain amino acid-derived acylcarnitines

 Propionylcarnitine

0.87 ± 0.05

 Isobutyrylcarnitine

0.70 ± 0.04

• Free fatty acids

 Arachidonic acid

0.92 ± 0.10

• Fatty acid-derived acylcarnitines

 Acetylcarnitine

0.69 ± 0.06

 Hexanoylcarnitine

0.62 ± 0.07

 Octanoylcarnitine

0.52 ± 0.09

 Octenoylcarnitine

0.42 ± 0.03

 Decanoylcarnitine

0.57 ± 0.12

 Decenoylcarnitine

0.51 ± 0.05

 Lauroylcarnitine

0.70 ± 0.11

 Dodecenoylcarnitine

0.64 ± 0.11

 Myristoylcarnitine

0.87 ± 0.04

 Tetradecenoylcarnitine

0.77 ± 0.11

 Tetradecadienoylcarnitine

0.67 ± 0.09

 Palmitoylcarnitine

0.88 ± 0.05

 Palmitoleoylcarnitine

0.77 ± 0.08

 Hexadecadienoylcarnitine

0.77 ± 0.09

 Oleylcarnitine

0.79 ± 0.06

 Linoleylcarnitine

0.67 ± 0.04

• Krebs’ cycle metabolomes

 Malate

0.85 ± 0.05

• Phospholipids

 Lysophosphatidylcholine (16:0)

0.94 ± 0.02

 Lysophosphatidylethanolamine (18:1)

1.79 ± 0.15

 Lysophosphatidylinositol (18:1)

1.33 ± 0.07

 Phosphatidic acid (34:1)

2.16 ± 0.39

 Phosphatidylcholine (36:1)

1.15 ± 0.04

 Phosphatidylcholine (36:2)

1.03 ± 0.02

 Phosphatidylethanolamine (34:1)

1.20 ± 0.05

 Phosphatidylethanolamine (38:4)

1.48 ± 0.21

 Phosphatidylserine (38:4)

1.74 ± 0.20

 Phosphatidylserine (40:6)

1.28 ± 0.11

  1. n = 37. Fold change of each metabolome was defined as a ratio of metabolome level at 2 weeks and the baseline metabolome level of each patient. Then, data are reported as mean ± standard error of the mean (SEM)
  2. Bold: Significantly increased when compared to baseline
  3. Italic: Significantly decreased when compared to baseline
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us